New York, New York 10032

  • Heart Failure

Purpose:

This investigation will be conducted as an interventional intention-to-treat clinical study in a population of end stage heart failure patients who meet specific inclusion and exclusion criteria. The multi-center study will be prospective, dual-armed, non-blinded (open-label) and randomized, comparing a treatment group receiving the Jarvik 2000 LVAS with Post-Auricular Connector to an active control group treated with the PMA approved Thoratec HeartMate® II LVAS for Destination Therapy.


Study summary:

Study Success for Primary Endpoint A will be established if the proportion of subjects in the Treatment Group meeting the Subject Success Criteria A, is determined to be non-inferior to that of the Control Group (at two years) according to the pre-specified statistical analysis. Subject composite success requires the subject to achieve the Effectiveness Endpoint: 1. Two year actuarial survival 2. Freedom from procedures to repair, or replace the implanted device 3. Freedom from stroke resulting in a Modified Rankin Score of >3 at the two-year follow-up Study Success for Primary Endpoint B will be established if the proportion of subjects in the Treatment Group meeting the Subject Success Criteria B is determined to be superior to that of the Control Group (at three years) according to the pre-specified statistical analysis. Subject composite success requires the subject to achieve the Effectiveness Endpoint: 1. Three year survival 2. Freedom from the serious adverse event of drive cable or pump pocket infection


Criteria:

Inclusion Criteria: 1. Cardiac transplantation ineligible. 2. Late stage heart failure in NYHA Class IIIb or IV for at least 45 of past 60 days. 3. Cardiac Index < 2.2 L / min / m2 4. LVEF = 25% or less 5. Patients on Optimal Medical Management (OMM) as defined in Section 9.2 OR dependent on intra-aortic balloon counter-pulsation for 7 days OR other temporary (indicated for 30 days use, or less) mechanical circulatory support for 7 days, OR supported with IV inotropes for 7 days and failing to respond. 6. BSA > 1.2 m2 and < 2.5 m2. Exclusion Criteria: 1. History of cardiac transplantation or left ventricular reduction procedure. 2. Clinical conditions, other than heart failure, which could limit survival to less than three years. 3. Cause of heart failure due to, or associated with, uncorrected thyroid disease, obstructive / restrictive cardiomyopathy, pericardial disease, amyloidosis, dermatomyositis, or active myocarditis. 4. Intolerance to anti-coagulation or anti-aggregation therapy required for post-operative therapy. 5. Known sensitivity to products of bovine origin. The Jarvik 2000 incorporates a Hemashield vascular graft. Patients with a known sensitivity to products of bovine origin should not be implanted. 6. Chronic immunosuppression.


NCT ID:

NCT01627821


Primary Contact:

Study Chair
Robert Jarvik, MD
Jarvik Heart, Inc. SPONSOR

Mary Blinder, MD
Phone: 212-397-3911 ext. 30
Email: clinical@jarvikheart.com


Backup Contact:

N/A


Location Contact:

New York, New York 10032
United States

Yoshifumi Naka, MD PhD
Phone: 212-305-0828

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: December 08, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.